Highlights
- Pirtobrutinib, a non-covalent BTK inhibitor, delivers significantly longer progression-free survival (PFS) than idelalisib/rituximab or bendamustine/rituximab in cBTKi-pretreated CLL/SLL.
- The safety profile of pirtobrutinib is more favorable, with lower rates of treatment discontinuation due to adverse events.
- Despite high crossover rates, pirtobrutinib offers a clinically meaningful new therapy for patients who have exhausted covalent BTK inhibitor options.
Clinical Background and Disease Burden
Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are the most prevalent adult leukemias in Western countries. The therapeutic landscape has shifted dramatically with the introduction of targeted agents, particularly covalent Bruton tyrosine kinase inhibitors (cBTKis) like ibrutinib and acalabrutinib, which have improved outcomes for many. However, disease progression on cBTKi therapy remains a substantial clinical challenge, as these patients often exhibit refractory disease and limited subsequent options. After progression on cBTKi, therapies like BCL-2 inhibitors (e.g., venetoclax), PI3K inhibitors (e.g., idelalisib), and chemoimmunotherapy regimens are used, but efficacy and tolerability are often suboptimal.
The emergence of non-covalent (reversible) BTK inhibitors, such as pirtobrutinib, has generated significant interest due to their distinct mechanism of action and potential to overcome resistance to cBTKi. The BRUIN CLL-321 study specifically addresses the unmet need for effective and tolerable therapies in patients with relapsed/refractory CLL/SLL previously treated with cBTKi.
Research Methodology
BRUIN CLL-321 (NCT04666038) is the first global, randomized, open-label, phase III trial to prospectively evaluate pirtobrutinib versus physician’s choice of idelalisib/rituximab (IdelaR) or bendamustine/rituximab (BR) in CLL/SLL patients pretreated with cBTKi. Key eligibility criteria included age ≥18 years, ECOG performance status 0-2, diagnosis per iwCLL 2018 criteria, and prior cBTKi exposure irrespective of other prior regimens.
Patients (n=238) were randomized 1:1 to pirtobrutinib (200 mg orally once daily, continuous) or IdelaR/BR (according to standard dosing). Stratification factors included del(17p) status and prior venetoclax exposure. Notably, patients in the control arm could cross over to pirtobrutinib upon independent review committee (IRC)-confirmed disease progression. The primary endpoint was IRC-assessed PFS. Key secondary endpoints included overall survival (OS), time to next treatment or death (TTNT), event-free survival (EFS), objective response rate (ORR), and safety. Treatment-emergent adverse events (TEAEs) were monitored up to 30 days post-treatment.
Key Findings
Baseline characteristics were balanced across arms (median age 66, 70% male, ~58% ECOG ≥1, ~45% del(17p) positive). The pirtobrutinib group achieved a median PFS of 14 months (95% CI 11.2-16.6) versus 8.7 months (95% CI 8.1-10.4) for IdelaR/BR, yielding a hazard ratio (HR) of 0.54 (95% CI 0.39-0.75; P=0.0002). Investigator-assessed PFS was even more favorable (median 15.3 vs. 9.2 months; HR 0.48).
Median EFS was 14.1 months for pirtobrutinib and 7.6 months for IdelaR/BR (HR 0.39). TTNT was substantially prolonged with pirtobrutinib (24 vs. 10.9 months; HR 0.37). The 18-month OS rate was similar between groups (73.4% vs. 70.8%; HR 1.09, P=0.7202). Notably, 76% of control patients crossed over to pirtobrutinib, diluting OS differences; sensitivity analyses adjusting for crossover confirmed the lack of significant difference in OS.
The ORR was higher with pirtobrutinib (69% vs. 50%). In terms of safety, any-grade TEAEs were reported in 93.1% of pirtobrutinib patients and 98.2% of IdelaR/BR patients. The most frequent TEAEs with pirtobrutinib were pneumonia (22.4%), anemia (19.8%), and neutropenia (18.1%), while IdelaR/BR was associated with diarrhea (31.2%), fever (26.6%), fatigue, and nausea (both 20.2%). After adjusting for treatment exposure, TEAE rates and treatment discontinuations were lower with pirtobrutinib (17.2% vs. 34.9%).
Mechanistic Insights
Pirtobrutinib is a highly selective, non-covalent (reversible) BTK inhibitor designed to retain activity against both wild-type and cBTKi-resistant C481-mutated BTK. This unique binding profile explains its ability to overcome resistance mechanisms that render cBTKis ineffective, providing a rational basis for its efficacy in heavily pretreated CLL/SLL populations.
Expert Commentary
The BRUIN CLL-321 trial represents a pivotal advance in the post-cBTKi setting. As summarized by Dr. Sharman and colleagues, the significant PFS and TTNT improvements, together with a more favorable safety profile, position pirtobrutinib as a preferred option for patients with limited remaining therapies. Current NCCN and ESMO guidelines recognize the need for novel agents in BTKi-refractory CLL, and pirtobrutinib’s accelerated FDA approval underscores its clinical impact.
Controversies and Limitations
The open-label design and high crossover rate (76%) from control to pirtobrutinib complicate OS interpretation, likely obscuring a true survival benefit. Although the study population is representative of real-world cBTKi-pretreated CLL/SLL, longer-term follow-up is needed to assess durability of response and late safety signals. The optimal sequencing of pirtobrutinib relative to other available agents, such as venetoclax, remains to be defined.
Conclusion
BRUIN CLL-321 is the first phase III trial to demonstrate the superiority of a non-covalent BTK inhibitor over established regimens in cBTKi-pretreated CLL/SLL. Pirtobrutinib offers substantial improvements in PFS, TTNT, and tolerability, providing a valuable new treatment option. Future studies should clarify its role in treatment sequencing and combination strategies to further optimize outcomes in this high-risk population.
References
1. Sharman JP, Munir T, Grosicki S, et al. Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321). J Clin Oncol. 2025;43(22):2538-2549. doi:10.1200/JCO-25-00166
2. NCCN Clinical Practice Guidelines in Oncology: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Version 1.2024.
3. Eichhorst B, et al. ESMO Clinical Practice Guidelines on chronic lymphocytic leukaemia. Ann Oncol. 2021;32(1):23-33.